Who we are

Directors

• 

  Christian Hill

  CEO

  

  Christian Hill

  CEO

  Christian is a seasoned Market Access professional with over 18 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

  Christian is a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland; he is also a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs).

• 

  Dawn Hill

  CFO

  

  Dawn Hill

  CFO

  MAP was founded by Dawn who has worked in national and local government departments ranging from Business, Agriculture, Education and Finance for over twenty years.

  This experience was primarily focused on business and administration processes and, importantly for MAP BioPharma, the simplification and efficiency of these processes.

  Dawn therefore founded MAP BioPharma Limited and combines business and administration expertise with contacts in the Health Service, Biotech and Pharmaceutical sectors to deliver valuable resources to support Market Access for medicines in the UK and Ireland.

• 

  Mark Harries

  COO

  

  Mark Harries

  COO

  Mark has in-depth understanding and experience of Health Technology Appraisals in the UK, Europe and US, optimising submissions to achieve successful outcomes for both primary care and specialist products including orphan drugs. Mark joined MAP in 2014, prior to this he spent 6 years at WG Consulting as Managing Director, driving one of the highest levels of performance within the market access industry. Previously, Mark was a pharmacist in the NHS for 14 years, with his last position being Lead Directorate Pharmacist of Paediatric and Adolescent Medicine at University College London Hospitals NHS Trust.

  Mark has worked on a diverse range of Market Access consultancy programmes in the EU and US and offers an in-depth understanding of the issues and opportunities for a product at all stages in its lifecycle with the ability to provide the right solutions for clients, which will resonate with a variety of stakeholders at a clinician or payer level.

• 

  Harriet Fear

  CCO

  

  Harriet Fear

  CCO

  Harriet has thrived on supporting life science and healthcare companies since 2003. She was appointed a Member of the Order of the British Empire (MBE) in the Queen’s Birthday 2016 Honours List in recognition of her services to the sector.

  Harriet was previously Chief Executive of One Nucleus, which became the largest international membership organisation in Europe for the sector during her tenure. She was pivotal in the company receiving a global award in 2016. Prior to this, Harriet headed UK Trade & Investments’ national life sciences trade team for over 5 years. She became a Diplomat at 18 with the British Foreign Office and served her country for 21 years in over 17 countries around the globe. Half her career was spent in the commercial field. During her varied Foreign Office career, she was Deputy Ambassador three times, Private Secretary to the Minister for Europe, led an evacuation of Brits out of the Congo and worked in Khymer Rouge territory with Scotland Yard on a hostage crisis. She now enjoys a calmer life in the UK!

  Harriet was appointed as the Prime Minister’s Business Ambassador for Life Sciences in January 2014. She continues in this role which sees her leading international delegations, speaking at major sector events, briefing visiting VIP’s and dignitaries from around the world and advising the Department of International Trade (DIT) on its strategy.

• 

  Andy Swarbrick

  Chairman

  

  Andy Swarbrick

  Chairman

  Andy brings with him 30 years of experience as a partner at Deloitte in Cambridge. He has a strong commercial background and an array of skills in financial management, strategic planning, HR and marketing both from an advisory perspective and from a career spent in various management roles within Deloitte. Pragmatic but with great attention to detail, an enquiring mind and a “can do” approach, he has much experience of building relationships and alliances, strong political skills and very significant experience in the owner manager/entrepreneurial and charity sectors. His various roles within the Deloitte Cambridge office ranged from Staff Partner, to Head of Business Development, to Head of Audit and to Senior Partner. He was for many years a Trustee of the Deloitte staff pension fund.

  His other current roles include Chairman of an executive search business and Non Exec Director of a regional law firm. For over 30 years he has been a trustee of an employee trust that owns a laboratory supply business. He also works with a number of charitable organisations, being a Trustee/Director of the Cambridge Arts Theatre, the Cambridge Union and until very recently the Arthur Rank Hospice Charity. He is also Chairman of the Cambridge Music Festival and a member of the Advisory Council of the London Philharmonic Orchestra.

Management

• 

  Simone Borley

  Executive Assistant

  

  Simone Borley

  Executive Assistant

  Simone brings to MAP a vast amount of experience in company and professional organisation, processes and protocols. Simone has worked for a variety of companies over her career including 8 years at First National Bank and 8 years with an Independent Financial Advisers firm, and joined us directly after completing the setup of a start-up research laboratory and office facility on Babraham Research Campus. Simone will be working very closely with Christian as his Executive Assistant, ensuring the smooth running of the administrative areas of the company.

• 

  Lynne Stoten

  Financial Controller

  

  Lynne Stoten

  Financial Controller

  Lynne is a member of ACCA and holds a BA Hons Degree in Business Economics from Anglian Ruskin University. Lynne has 20 years’ experience working in the finance departments of technology companies which began their lives as start-up businesses, established to develop new technology born from Cambridge University. Lynne has established financial systems and processes which have ensured continuity of the finance function through their transitional program towards to a successful exit strategy and beyond. Lynne joined MAP in June 2017, assisting Dawn Hill, MAP’s Chief Financial Officer, to grow the strong and efficient finance functions within MAP.

• 

  Sarah Borley

  Reception Administrator

  

  Sarah Borley

  Reception Administrator

  Sarah joined MAP as a Receptionist Administrator bringing her experience of administration and customer care. Having studied childcare at Cambridge Regional College and worked for 5 years within a nursery school as a Room Leader, working with children between the ages of 0-5, before changing her career direction to Receptionist. Sarah has also been a member of the Girlguiding Association for 19 years, and has been volunteering for 6 years as a Leader, providing leadership, organisation and independence for girls and young women.

Service Development Team

• 

  Andrew Gapper

  Associate Director Service Development

  

  Andrew Gapper

  Associate Director Service Development

  Andrew has over twenty five years’ experience with international biotech and pharmaceutical companies, in a variety of commercial roles, most recently as Associate Director Commercial Training EU for Sanofi Genzyme. He has successfully managed and implemented a range of market access and reimbursement projects, especially in highly specialised and ultra-orphan disease areas.

• 

  Samir Sattar

  Consultant Service Development

  

  Samir Sattar

  Consultant Service Development

  Samir graduated with a Masters in Natural Science where he specialised in Neuroscience. He has a broad experience in scientific research, interning at Cambridge Institute for Medical Research where he conducted research within neurodegenerative diseases. He followed this up by interning at Getz Pharmaceuticals, rotating between the New Product Development (NPD) and Scientific Research and Development (SR&D) departments, gaining valuable insight into the pharmaceutical industry before joining MAP, where he leads the development of the MAP Online service as well as working on market access related consulting projects in major global markets.

• 

  John Nikolettos

  Associate Consultant Service Development

  

  John Nikolettos

  Associate Consultant Service Development

  John graduated from the University of Reading with a Masters degree in Pharmacy (MPharm). During his academic studies he interned at the Biomedical Research Foundation of the Academy of Athens (BRFAA) obtaining additional scientific and research experience. John then went on to pursue a PhD in Pharmaceutics, at the University of Bath where the focus of his doctorate was on the development of dissolution studies for intra-articular formulations. During his time at the University of Reading, John was elected president of the Greek-Cypriot Society and at the University of Bath he was voted the Graduate Academic Representative for the Pharmacy & Pharmacology department. John joined MAP as an Associate Consultant and is involved in updating and improving the information available on the MAP websites, while working with clients, offering assistance in various consulting projects.

• 

  Catherine Mak

  Associate Consultant Market Access

  

  Catherine Mak

  Associate Consultant Market Access

  Catherine graduated with an MPharm degree from University College London. Following successful completion of her qualifying year, she registered as a pharmacist and started studying for an Msc in Economic Evaluation in Healthcare at City, University of London. During her pharmacy training, Catherine gained clinical experience in both primary and secondary care in the UK, in the not-for-profit health organisation HealthServe and the healthcare system in Singapore. She has undertaken neuroscience research at the UCL Institute of Neurology and research in nanotechnology drug delivery at the Melbourne ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. Before joining MAP as an Associate Consultant in October 2017, Catherine worked on a variety of health economic models and enjoys drawing on her experience in pharmacy, health economics and research to help communicate economic and clinical outcomes effectively.

• 

  Nicole Rowlands

  Associate Consultant Service Development

  

  Nicole Rowlands

  Associate Consultant Service Development

  Nicole has over 5 years experience in customer service roles, primarily providing support for small to medium size businesses. Nicole graduated from the University of Greenwich with a Diploma in Healthcare. She joins us in the Service Development team to manage and develop client relationships.

• 

  Oliver Hulisz

  Web Design and Development

  

  Oliver Hulisz

  Web Design and Development

  Oliver Hulisz is head of web design and development at MAP. He has developed more than 50 websites for a range of companies and specialises in WordPress.

  Oliver provides day to day maintenance and updates for the continuously improving and evolving MAP websites as well as ensuring that our technical approach to delivering maximum value to our online clients is always fresh and making the most of the latest available developments. His company 72dpi netzbüro is based in Essen, Germany.

Market Access team

• 

  Gemma Gapper

  Associate Director Market Access

  

  Gemma Gapper

  Associate Director Market Access

  With nearly 20 years’ experience in the life sciences industry Gemma brings a breadth and depth of knowledge of commercial sales and marketing, and market access processes across the UK, which have achieved funding for novel products, as well as supporting companies to ensure the commissioning environment can support implementation of funding decisions.

• 

  Jade Marshall

  Associate Director Health Economics

  

  Jade Marshall

  Associate Director Health Economics

  Jade has written and supported more than 20 health technology appraisals (HTAs) to HTA agencies in the UK (NICE, SMC, AWMSG), Sweden (TLV), Ireland (NCPE) and Canada (CADTH, INESSS). She specialises in providing strategic advice for health technology assessments of rare diseases and is responsible for constructing value stories, conducting systemic literature reviews and the design and development of health economics models such as cost-utility, cost-effectiveness and budget impact models.

  Jade has a Masters in Economic Evaluation in Healthcare from City University London. She has a First Class Masters degree in Engineering Mathematics from the University of Bristol where her thesis focussed on dynamical infectious disease modelling. Prior to this, Jade had a position within a NHS public health team, supporting training of healthcare professionals.

• 

  Lizzy Balman

  Senior Scientific Consultant

  

  Lizzy Balman

  Senior Scientific Consultant

  Lizzy has over 9 years experience in market access consulting for the pharmaceutical industry, and has in-depth experience of health technology appraisals in both the UK and Europe, where she inputs into the strategy, clinical writing, systematic literature reviews, evidence interpretation and alignment of the clinical evidence and health economic modelling. She also has a critical understanding of appraisal processes and timelines and has managed numerous successful submissions through to final recommendations, often within tight deadlines. She has broad experience developing clinical and payer communications, as well as research interviews and advisory panels. Lizzy has worked extensively in rare diseases, has a keen interest in genetic disorders, and has worked across diverse therapeutic areas including oncology, haematology, respiratory, ophthalmology and neurology (multiple sclerosis).

  In her earlier academic career Lizzy graduated from the University Glasgow with a degree in Genetics followed by a Masters of Research in Biomedical Sciences. She then worked in vaccine research at the Edward Jenner Institute where she specialised in researching the basis of dendritic cell activation, and went on to complete a PhD in this area.

• 

  Juan Jose Garcia Sanchez

  Consultant Health Economist and Clinical Affairs

  

  Juan Jose Garcia Sanchez

  Consultant Health Economist and Clinical Affairs

  Juan holds a Masters degree in Pharmacy from the University of Manchester, a Nursing Diploma from the University of Seville and a Masters of Science in Health Economics from the University of York.

  Juan has considerable technical experience, which he gained through his work in global market access and health economics teams in consultancy. He has undertaken and led projects involving systematic literature reviews, meta-analyses, value dossiers and cost-effectiveness analyses to support a number of HTA submissions, among other market access projects at global and national levels. He has been involved in projects covering a wide range of disease areas including oncology, auto-immune diseases or rare diseases. Juan acquired a sound clinical knowledge during his extensive work in a number of hospitals in England and Spain.

• 

  Brian Gavin

  Market Access & Government Affairs Consultant Republic of Ireland

  

  Brian Gavin

  Market Access & Government Affairs Consultant Republic of Ireland

  Brian Gavin has over twenty-five years’ experience in the healthcare sector across a range of senior management positions both in Ireland and internationally. Most of his industry experience was with GlaxoSmithKline where he held a number of senior management positions including Global Commercial Strategy Manager for Seretide, Commercial Director for GSK Ireland and subsequently Corporate Affairs Director with the company.

  Since 2009, Brian has provided consultancy services to a broad range of pharmaceutical companies including Almirall, Janssen, Biogen IDEC, Reckitt Benckiser, Mundipharma, Takeda, Bausch & Lomb, Bayer and InterMune.

  He has extensive experience in the submission of HTA’s to the National Centre for Pharmacoeconomics and has completed desk and field based research across a broad range of therapy areas. Developed over a number of years Brian has a comprehensive network of contacts across a broad spectrum of stakeholders in the Irish healthcare environment.

• 

  Mark Edwards

  Medical and R&D Advisor

  

  Mark Edwards

  Medical and R&D Advisor

  Mark Edwards [BSc (hons) MB BS FRCA FSB] is a medically-qualified (anaesthesia and critical care) and GMC-registered drug developer with over 20 years’ pharma R&D experience. Formerly, he was a Global Clinical R&D Director and then Director of Science and Medical Public Affairs at Pfizer. He has worked at all phases of clinical development across a wide variety of therapeutic areas.

  His experience has also included the establishment of major R&D projects at the interfaces between academia, the NHS and the biopharma industry e.g. having helped lead the establishment of 1) MRC/industry pre-competitive consortia in COPD and RA and 2) the UK Government’s Translational Research Partnership Programme.

  Mark is also R&D Director of the Ethical Medicines Industry Group, R&D Director of OBN, Pharmaceutical Business Adviser for South East Health Technologies Alliance, Non-Executive Director of MRC Technology and a member of Manchester University’s Drug Discovery and Life Sciences Advisory Boards. He also supports a range of public and charitable sector organisations in the UK.

Public Affairs Team

• 

  Tessa Hughes

  Head of Health Policy and Public Affairs

  

  Tessa Hughes

  Head of Health Policy and Public Affairs

  Tessa Hughes has over ten years’ experience in policy and public affairs. She has worked for charities and spent 7 years within two award-winning healthcare communications consultancies working across a range of areas, including corporate communications, cancer, cardiovascular disease and diabetes. She has a detailed understanding of the UK health policy environment, including access to medicines issues, levers and incentives and new care models. She has managed a range of successful campaigns, including securing better access to medicines and support for improved cancer awareness.

• 

  Chris Mockler

  Public Affairs Health Consultant

  

  Chris Mockler

  Public Affairs Health Consultant

  Chris has an extensive background in public affairs. He worked Parliament and with Shadow and actual Ministers. Later he was appointed as a Special Adviser to a local government Cabinet Minister and subsequently to a health Minister.
  He has been a public affairs consultant for many years to pharmaceutical / biotech companies. This was in their individual capacity and to groups of companies which came together for specific projects.

  He has therefore been able to help businesses achieve their commercial objectives in public affairs by helping in their dealings with government officials in the Department of Health, DBEIP, DFID and the Treasury; with official health organisations such as NHSE, PHE, NICE and the MHRA; and with Parliamentarians and Ministers, together with their political advisers.
  This work has involved all parts of the UK as well as key bodies like the European Commission and European Parliament, EFPIA, the WHO and PhRMA.

• 

  Sarah Walker

  Public Affairs Consultant

  

  Sarah Walker

  Public Affairs Consultant

  Sarah has over twenty-five years’ experience working in policy and public affairs roles. She worked for a Member of Parliament and for a political publication, before joining a leading public affairs consultancy with a specialist unit dedicated to the health sector. She has worked on both corporate and disease specific public affairs programmes for clients including Merck Sharp & Dohme, Sandoz and the London and Thames Valley Pharmaceutical Group which included some of the UK’s largest pharmaceutical companies. Outside healthcare she has experience of developing strategic public affairs programmes for leading companies including Marks & Spencer and Tate & Lyle. Since joining MAP BioPharma her work has included a significant number of projects in the rare disease arena and she has a detailed knowledge of the key stakeholders in this sector. Sarah has a strong network of contacts and a detailed understanding of the workings of Parliament and the development of policy.

• 

  Erin Fulton-McAlister PhD

  Associate Consultant Health Policy and Public Affairs

  

  Erin Fulton-McAlister PhD

  Associate Consultant Health Policy and Public Affairs

  Erin brings unique insights into MAP’s policy and public affairs work through her time as a research scientist and broad experience working within the civil service, local government departments, and on an EU level. Erin is skilled at translating complex scientific information into messages that will resonate with lay and policy-maker audiences.

  Before joining MAP, Erin worked extensively in infectious disease and drug discovery research, often focussing on infections of vulnerable populations such as patients with respiratory conditions such as cystic fibrosis, neonates, or those undergoing immunosuppressive therapy. Following graduation from the University of York with a degree in Biology, she worked for 3 years at Dstl Porton Down researching novel medical countermeasures against potential biothreat agents. She then completed a PhD at Imperial College London, during which she examined how antibiotic resistance genes are spread amongst bacteria, then undertook post-doctoral studies into the efficacy of novel antibiotics.

Legal Team

• 

  Paul Ranson

  Legal Consultant

  

  Paul Ranson

  Legal Consultant

  Paul Ranson is a lawyer with some 30 years pharmaceutical industry experience. He was formerly in-house lawyers for Smith Kline, Merck Sharp & Dohme and Eli Lilly before going in to private practice where he was a partners of two large international law firms Fasken Martineau and Pinsent Masons. His particular field of expertise is in the EU regulatory and commercial laws affecting pharmaceutical and device companies. This includes some 50 major licensing and product acquisition/divestment transactions. He has been recommended in the main legal directories for life sciences lawyers (Chambers, Legal 500 and others) for some 15 years.

  Beyond legal practice, Paul is a non-executive director of two pharmaceutical companies. He lectures widely and has written or co-written some 10 books or reports on legal issues including collaborations, product liability, outsourcing, pricing and reimbursement and manufacturing and clinical research. He is also the main author of the legal section of the Manchester University MSc on Pharmaceutical Licensing. He is the legal advisor to the Ethical Medicines Industry Group, the trade association for mid-sized pharma companies. He spent 5 years on an IEC.

• 

  Angelika Gornikowska

  Paralegal

  

  Angelika Gornikowska

  Paralegal

  Angelika has begun her legal journey at the University of Wroclaw in Poland where she obtained a Masters Degree. Having developed an interest in the common law system, Angelika has decided to pursue a Graduate Diploma in Law (GDL) course at the BPP University which she will complete in June 2018. Prior to joining MAP, Angelika has gained experience in working with multinational clients, in particular by conducting research and preparing various legal documents.

Philanthropy

• 

  Philanthropy

  

  Philanthropy

  We support Help for Hope which promotes equal opportunities for all children.

  It was founded by a group of like minded life science professionals, one of whom recently helped us on a personal level. We were touched by their ethical approach whereby all admin costs for the charity are paid for by their own businesses.

  This means that 100% of our donations directly support specific projects to help underpriviledged children, providing them with opportunities to become agents of a better future. Link: help-for-hope.org